These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 28945228)

  • 1. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
    Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
    Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
    Liu J; Hong J; Ahn KS; Go J; Han H; Park J; Kim D; Park H; Koh Y; Shin DY; Yoon SS
    Leuk Lymphoma; 2019 Oct; 60(10):2532-2540. PubMed ID: 30947576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.
    Bozec A; Ebran N; Radosevic-Robin N; Chamorey E; Yahia HB; Marcie S; Gautier M; Penault-Llorca F; Milano G
    Head Neck; 2017 Jan; 39(1):151-159. PubMed ID: 27507562
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
    Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
    O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR
    PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
    Jin L; Jin MH; Nam AR; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Lett; 2017 Dec; 411():162-170. PubMed ID: 29024814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
    Park E; Park J; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Int J Oncol; 2012 Apr; 40(4):1259-66. PubMed ID: 22159814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
    Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
    Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
    Lee TL; Yeh J; Van Waes C; Chen Z
    Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
    Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
    PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
    Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G
    J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma.
    Dong L; Liu C; Sun H; Wang M; Sun M; Zheng J; Yu X; Shi R; Wang B; Zhou Q; Chen Z; Xing B; Wang Y; Yao X; Mei M; Ren Y; Zhou X
    Cancer Lett; 2024 Jul; 593():216956. PubMed ID: 38735381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
    Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J
    Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
    Rosich L; Saborit-Villarroya I; López-Guerra M; Xargay-Torrent S; Montraveta A; Aymerich M; Villamor N; Campo E; Pérez-Galán P; Roué G; Colomer D
    Haematologica; 2013 Nov; 98(11):1739-47. PubMed ID: 23850807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.